The constipation treatment market is expected to grow from USD 18.82 billion in 2022 to USD 29.29 billion by 2028, at a CAGR of 7.60%. The market growth is attributed to the rising prevalence of chronic constipation, growing investment in healthcare, increasing sedentary lifestyle, and the presence of a huge patient population base in the region.
What is Constipation Treatment?
Constipation is a condition in which a person has difficulty passing stools. It is usually caused by a lack of fiber in the diet, not drinking enough fluids, or not exercising regularly. Constipation can also be caused by certain medications, such as pain relievers and antidepressants.
There are many different ways to treat constipation. Lifestyle changes, such as eating a high-fiber diet, drinking plenty of fluids, and exercising regularly, can often help. If lifestyle changes are not enough, over-the-counter or prescription laxatives may be used.
Market Drivers
The following factors are driving the growth of the constipation treatment market:
- Rising prevalence of chronic constipation: Chronic constipation is a long-term condition that can be difficult to treat. It is estimated that up to 25% of the population suffers from chronic constipation.
- Growing investment in healthcare: Governments and private companies are investing heavily in healthcare, which is leading to the development of new and more effective constipation treatments.
- Increasing sedentary lifestyle: Sedentary lifestyles are a major risk factor for constipation. People who sit for long periods of time are more likely to experience constipation.
- Presence of a huge patient population base: The global population is aging, and older people are more likely to experience constipation. This is because the digestive system slows down with age.
Market Segmentation
The constipation treatment market can be segmented by type, treatment, method of administration, and end use.
By type, the market is segmented into:
- Chronic idiopathic constipation (CIC)
- Irritable bowel syndrome with constipation (IBS-C)
- Opioid-induced constipation (OIC)
By treatment, the market is segmented into:
- Pharmacological treatment
- Non-pharmacological treatment
By method of administration, the market is segmented into:
- Oral
- Parenteral (subcutaneous injection)
By end use, the market is segmented into:
- Hospital pharmacies
- Drug stores
- Independent pharmacies
Regional Trends
North America is expected to account for the largest share of the constipation treatment market during the forecast period. This is due to the high prevalence of chronic constipation in the region, as well as the growing investment in healthcare.
The Asia-Pacific is expected to grow at the highest CAGR during the forecast period. This is due to the rising prevalence of bowel and gastric diseases, growth in healthcare expenditure, surging demand for diagnostic tests, rise in disposable income, strong focus on early diagnosis & treatment of GI diseases, and strong proliferation of healthcare infrastructure.
Key Players
The following are some of the key players operating in the constipation treatment market:
- Takeda Pharmaceutical Company Ltd. (Japan)
- Ironwood Pharmaceuticals, Inc. (US)
- Salix Pharmaceuticals, Inc. (US)
- Abbott Laboratories
- AstraZeneca Plc (UK)
- Cosmo Pharmaceuticals NV (Ireland)
- Sanofi S.A. (France)
- AbbVie's Inc
- Bayer AG (Germany)
- Bausch Health Companies Inc. (Canada)
COVID-19 Impact Analysis
The COVID-19 pandemic had a moderate impact on the constipation treatment market. The pandemic adversely affected international trade activities and supply chains across the globe. The pandemic resulted in a diversion of the medical field towards treating COVID-19, thus the funding for R&D activities pertaining to constipation treatment has been reduced, thereby affecting the market growth amid the pandemic.
Conclusion
The constipation treatment market is expected to grow significantly during the forecast period. This growth is attributed to the rising prevalence of chronic constipation, growing investment in healthcare, increasing sedentary lifestyle, and the presence of a huge patient population base in the region.
Write a comment